Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS)
CNY 29.1
(-2.68%)
CNY 29.1
(-2.68%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -199.97 Million CNY | -112.6% |
| 2022 | 2.56 Billion CNY | -35.7% |
| 2021 | 5.81 Billion CNY | 180.43% |
| 2020 | 1.98 Billion CNY | 1927.97% |
| 2019 | 101.52 Million CNY | 15.3% |
| 2018 | 88.2 Million CNY | 77.14% |
| 2017 | 48.31 Million CNY | -14.32% |
| 2016 | 56.26 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -84.82 Million CNY | 97.34% |
| 2024 Q3 | -116.16 Million CNY | -26.95% |
| 2024 Q2 | -91.5 Million CNY | -937.26% |
| 2023 Q2 | 145.9 Million CNY | 306.92% |
| 2023 FY | - CNY | -112.6% |
| 2023 Q1 | -70.51 Million CNY | 43.18% |
| 2023 Q3 | -93.16 Million CNY | -163.85% |
| 2023 Q4 | -332.17 Million CNY | -256.53% |
| 2022 Q2 | 945.61 Million CNY | -62.41% |
| 2022 FY | - CNY | -35.7% |
| 2022 Q4 | -124.09 Million CNY | -136.17% |
| 2022 Q3 | 343.06 Million CNY | -63.72% |
| 2022 Q1 | 2.51 Billion CNY | 120.37% |
| 2021 Q1 | 1.33 Billion CNY | 2.95% |
| 2021 Q3 | 543.63 Million CNY | -80.57% |
| 2021 FY | - CNY | 180.43% |
| 2021 Q4 | 1.14 Billion CNY | 109.97% |
| 2021 Q2 | 2.79 Billion CNY | 109.16% |
| 2020 Q3 | 165.78 Million CNY | -70.56% |
| 2020 Q1 | 53.3 Million CNY | 86.64% |
| 2020 FY | - CNY | 1927.97% |
| 2020 Q4 | 1.29 Billion CNY | 683.73% |
| 2020 Q2 | 563.07 Million CNY | 956.24% |
| 2019 Q3 | 30.17 Million CNY | 17.32% |
| 2019 FY | - CNY | 15.3% |
| 2019 Q4 | 28.56 Million CNY | -5.33% |
| 2019 Q2 | 25.71 Million CNY | 65.67% |
| 2019 Q1 | 15.52 Million CNY | -33.76% |
| 2018 Q4 | 23.43 Million CNY | 0.0% |
| 2018 FY | - CNY | 77.14% |
| 2017 FY | - CNY | -14.32% |
| 2016 FY | - CNY | 0.0% |